Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2021-07-14 00:00:00 ET · period of report 2021-07-12 · accession 0000886163-21-000108 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-07-14 | 2021-07-12 | LGND | Cochran Jennifer R. | Dir | A - Grant | $0.00 | +1,161 | 1,161 | New | $0 |
| D | 2021-07-14 | 2021-07-12 | LGND | Cochran Jennifer R. | Dir | A - Grant | $0.00 | +4,508 | 4,508 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-07-12 | A | A | 1,161 | $0.00 | 1,161 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2021-07-12 | A | A | 4,508 | $0.00 | 4,508 | D | $126.36 · 2022-07-12 to 2031-07-12 | 4,508 Common Stock | (F1) The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date. |